No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
206 |
4. Check minimum number of eventsNone |
206 |
5. Include endpointsNone |
206 |
6. Filter based on genotype QC (FinnGen only) |
180 |
Control definitions (FinnGen only)
- Control exclude
- AB1_OTHER_BACTERIAL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Listeriosis
based on the number of shared cases.
Similar with more cases:
- Other bacterial diseases
- Other bacterial diseases, including avohilmo
- Certain infectious and parasitic diseases
- Certain infectious and parasitic diseases, including avohilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1333 | 676 | 639 |
| Only index persons | 984 | 554 | 430 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 69.92 | 69.30 | 70.68 |
| Only index persons | 70.94 | 69.41 | 72.91 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 180 | 93 | 87 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.04 |
| Median age at first event (years) | 69.95 | 66.33 | 73.81 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 183
- Matched controls
- 1830
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A32.7
ICD-10 Finland
Listerial sepsis
+∞
156.6
127
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
61.7
101.9
59
14
R50.9
ICD-10 Finland
Fever, unspecified
7.3
34.7
67
135
A41.9
ICD-10 Finland
Sepsis, unspecified
+∞
31.1
29
*
G01*A32.1
ICD-10 Finland
Listerial meningitis
+∞
25.6
24
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
10.8
24.2
28
30
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.6
19.8
63
189
L04AX01
ATC
azathioprine; systemic
16.2
18.0
29
21
A46
ICD-10 Finland
Erysipelas
6.5
17.1
31
56
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
+∞
16.9
16
*
TK800
NOMESCO Finland
Hemodialysis
35.1
15.1
19
6
WX892
NOMESCO Finland
Monitored bed care
6.0
14.9
29
56
A41.8
ICD-10 Finland
Other specified sepsis
+∞
14.8
14
*
B03XA02
ATC
darbepoetin alfa; parenteral
21.4
14.6
21
11
ZX120
NOMESCO Finland
Intravenous
4.6
14.5
40
105
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.5
13.8
65
249
N17.9
ICD-10 Finland
Acute renal failure, unspecified
12.4
13.5
24
22
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
5.4
13.4
29
62
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
12.8
100
512
B01AA03
ATC
warfarin; systemic
3.3
12.8
66
266
A32.1
ICD-10 Finland
Listerial meningitis and meningoencephalitis
+∞
12.6
12
*
A32.8
ICD-10 Finland
Other forms of listeriosis
+∞
12.6
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.1
12.4
39
113
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
16.1
12.1
19
13
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.1
12.0
38
110
C03CA01
ATC
furosemide; systemic
3.0
11.9
97
503
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
5.7
11.6
23
45
H02AB06
ATC
prednisolone; systemic
3.0
11.6
112
635
L04AA06
ATC
mycophenolic acid; systemic
37.6
11.4
14
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
18.6
11.4
17
10
M05BA04
ATC
alendronic acid; oral
3.9
10.8
37
113
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.6
10.3
26
63
ZXD05
NOMESCO Finland
Urgent procedure
2.8
10.2
73
347
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.7
10.2
25
59
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.8
10.1
110
647
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.8
9.9
34
104
J01MA12
ATC
levofloxacin; systemic
3.1
9.7
52
210
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.1
9.6
21
45
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
13.4
9.6
16
13
G00.9
ICD-10 Finland
Bacterial meningitis, unspecified
+∞
9.5
9
*
0270X
ICD-9 Finland
Other zoonotic bacterial diseases, Listeriosis[LISTERIOSIS ALIA (EI SYNNYNNÄINEN)]
+∞
9.5
9
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
9.3
73
361
Z49.1
ICD-10 Finland
Extracorporeal dialysis
38.8
9.1
11
*
J01MA02
ATC
ciprofloxacin; systemic
2.6
9.1
95
540
A11CC03
ATC
alfacalcidol; systemic
11.6
9.0
16
15
UJF32
NOMESCO Finland
Coloscopy
2.6
8.5
66
322
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
8.5
55
245
N18.0
ICD-10 Finland
End-stage renal disease
94.2
8.5
9
*
I50.9
ICD-10 Finland
Heart failure, unspecified
2.9
8.5
50
212
N02AA05
ATC
oxycodone; systemic
2.7
8.2
55
249
B01AB05
ATC
enoxaparin; parenteral
2.5
8.1
77
414
JN4BD
NOMESCO Finland
Extensive body CT
3.5
8.0
31
102
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
9.1
8.0
16
19
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.2
8.0
35
125
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.8
7.9
50
219
R2110
NOMESCO Finland
Giving the first information
4.7
7.9
19
44
127
Kela drug reimbursment
Transplant complication
26.3
7.7
10
*
XW000
NOMESCO Finland
Bone marrow biopsy
6.5
7.6
19
32
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
4.5
7.5
19
46
I50.0
ICD-10 Finland
Congestive heart failure
3.3
7.4
30
102
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.5
7.3
27
86
A32.9
ICD-10 Finland
Listeriosis, unspecified
+∞
7.3
7
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.1
7.3
21
56
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
3.6
7.3
26
81
WX002
NOMESCO Finland
Sedation and analgesia
2.6
7.1
51
237
SPAT1229
SPAT
Assessment of need for aid
3.6
7.1
25
77
L01BA01
ATC
methotrexate; systemic
7.2
7.0
16
24
A03FA01
ATC
metoclopramide; systemic, rectal
2.5
6.9
53
254
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
41.6
6.8
8
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
7.9
6.5
14
19
L04AA01
ATC
[U] ciclosporin
15.0
6.5
10
7
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
6.5
69
383
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
+∞
6.3
6
*
L04AD02
ATC
tacrolimus; systemic
+∞
6.3
6
*
C03DA01
ATC
spironolactone; oral
2.7
6.1
37
157
A10AC01
ATC
insulin (human); parenteral
3.5
6.1
22
69
A10AB05
ATC
insulin aspart; parenteral
3.4
6.0
23
75
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
105
6.35
25.21
2.4
1.4
—
—
—
0
0
48
101
6.09
23.06
16.6
4.9
12.19
10.28
mmol/l
0.88
48
96
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
29
37
9.13
21.93
5.0
2.1
0.34
0.44
iu/ml
0.49
17
23
29
40
8.43
20.56
2.4
1.6
2.79
0.24
ug/l
1.86
29
29
75
255
4.29
19.93
2.7
1.8
—
—
—
0
0
33
75
5.15
14.22
3.6
2.8
1.99
2.03
mmol/l
0.02
25
57
25
49
5.75
12.61
3.9
2.3
—
—
—
0
0
55
200
3.50
12.54
2.2
1.7
—
—
—
0
0
121
697
3.17
12.49
13.9
3.9
32.10
35.71
g/l
7.32
115
653
21
36
6.46
12.09
2.2
1.2
—
—
—
0
0
27
64
4.78
10.99
3.9
1.5
6.96
11.41
iu/ml
0.35
11
16
24
52
5.16
10.83
1.9
1.1
—
—
—
0
0
132
844
3.02
10.49
26.1
8.7
4.79
4.03
e9/l
1.66
121
726
49
190
3.16
9.86
2.2
1.8
—
—
—
0
0
23
54
4.73
9.43
8.5
4.4
5.03
4.31
ratio
0.09
16
28
21
32
7.27
8.97
2.0
1.3
—
—
—
0
0
81
429
2.59
8.93
3.5
2.1
3.97
3.06
mg/l
1.88
72
358
14
10
15.03
8.85
1.4
1.2
—
—
—
0
0
18
37
5.29
8.56
2.1
1.4
—
—
—
0
0
15
15
10.78
8.20
2.2
1.8
—
—
—
0
0
25
70
3.98
8.18
1.7
1.3
—
—
—
0
0
14
14
10.72
7.68
2.3
1.9
—
—
—
0
0
18
34
5.75
6.67
1.7
1.4
—
—
—
0
0
92
575
2.21
6.43
4.4
3.2
5012.32
1194.01
ng/l
1.80
87
490
121
856
2.22
6.05
22.0
5.8
1.19
1.22
mmol/l
4.48
108
738
13
18
7.68
6.04
1.4
1.4
—
—
—
0
0
14
22
6.80
5.99
2.1
1.5
—
—
—
0
0
112
774
2.15
5.87
18.5
5.2
1.19
1.22
mmol/l
4.36
105
706
16
41
4.18
5.85
4.8
2.0
2.10
1.57
mg/l
1.09
16
33
17
36
5.10
5.78
3.7
1.9
—
—
—
0
0
13
20
6.91
5.67
1.4
1.5
—
—
—
0
0
8
5
16.63
5.46
2.5
1.6
—
—
—
0
0
8
5
16.63
5.46
2.5
1.6
—
—
—
0
0
8
5
16.63
5.46
2.5
1.6
—
—
—
0
0
8
5
16.63
5.46
2.5
1.6
—
—
—
0
0
36
160
2.56
5.42
8.9
2.9
0.83
1.88
mmol/l
1.37
29
140
40
188
2.44
5.36
21.0
6.6
1.25
1.11
mmol/l
0.08
33
164
14
26
5.74
5.34
1.4
1.4
—
—
—
0
0
17
49
3.72
5.31
2.6
1.5
—
—
—
0
0
14
27
5.52
5.20
1.4
1.4
—
—
—
0
0
13
23
6.00
5.17
1.8
1.3
1202.00
1589.06
e6/l
—
6
18
25
94
2.92
5.16
2.2
1.5
—
—
—
0
0
12
20
6.34
5.00
3.9
2.2
13.29
16.10
%
1.72
12
20
75
477
1.97
4.62
5.3
3.1
0.27
0.37
e6/l
0.48
64
337
9
11
8.53
4.61
2.3
1.9
—
—
—
0
0
9
11
8.53
4.61
2.3
1.9
—
—
—
0
0
9
11
8.53
4.61
2.3
1.9
—
—
—
0
0
7
5
14.47
4.61
1.1
1.2
—
—
—
0
0
7
5
14.47
4.61
1.4
1.2
—
—
—
0
0
7
5
14.47
4.61
1.1
1.2
—
—
—
0
0
7
5
14.47
4.61
1.0
1.4
—
—
—
0
0
17
55
3.31
4.49
4.1
1.6
—
—
—
0
0
94
654
1.90
4.37
6.3
4.1
94.13
48.80
ng/l
0.48
79
506
8
9
9.23
4.32
1.1
1.0
—
—
—
0
0
12
25
5.06
4.27
1.4
1.5
—
—
—
0
0
23
94
2.65
4.07
8.3
2.8
23.00
24.43
mmol/l
2.18
23
94
99
712
1.85
4.05
6.2
2.6
—
—
estimate
—
0
0
42
228
2.09
3.94
13.5
5.8
104.60
103.93
mmol/l
0.37
42
228
8
12
6.91
3.71
5.8
2.3
—
—
—
0
0
7
9
8.03
3.59
1.1
1.3
—
—
—
0
0
13
36
3.81
3.58
1.2
1.3
—
—
—
0
0
9
17
5.51
3.56
1.3
1.4
—
—
—
0
0
23
102
2.44
3.46
14.1
8.0
92.96
93.22
%
0.05
23
102
60
387
1.82
3.36
5.1
2.4
—
—
—
0
0
96
712
1.73
3.31
3.6
2.4
86.32
78.09
nmol/l
1.76
91
621
50
306
1.87
3.30
2.4
1.7
1048.49
1149.16
nmol/l
0.37
41
224
6
7
8.81
3.28
1.3
2.0
—
—
—
0
0
12
34
3.70
3.26
1.3
1.3
—
—
—
0
0
48
291
1.88
3.26
4.8
2.9
0.83
1.14
e6/l
0.44
32
142
11
29
3.97
3.24
3.3
2.4
7.48
7.93
kpa
0.42
11
29
9
20
4.67
3.15
1.0
1.0
—
—
u/ml
—
0
0
8
16
5.18
3.08
1.1
1.3
17.25
12.94
u/l
—
8
16
5
5
10.23
2.99
1.2
1.2
—
—
—
0
0
5
5
10.23
2.99
4.2
1.0
—
—
—
0
0
5
5
10.23
2.99
1.2
1.2
—
—
—
0
0
5
5
10.23
2.99
1.2
1.0
—
—
—
0
0
7
13
5.55
2.89
6.0
1.4
-0.57
1.57
mmol/l
—
7
13
10
28
3.72
2.83
1.3
1.4
—
—
—
0
0
10
28
3.72
2.83
1.3
1.4
—
—
—
0
0
44
271
1.82
2.82
5.0
3.1
3.34
2.46
e6/l
0.22
29
124
9
23
4.06
2.81
2.7
1.2
—
—
—
0
0
9
23
4.06
2.81
2.9
1.2
—
—
—
0
0
9
23
4.06
2.81
2.9
1.2
—
—
—
0
0
97
750
1.62
2.66
3.2
2.6
—
—
—
0
0
96
746
1.60
2.54
2.6
2.2
95.23
95.63
pmol/l
0.02
61
384
6
12
5.13
2.42
1.0
1.2
4.80
4.63
u/l
—
6
12
8
22
3.75
2.39
3.0
1.2
—
—
—
0
0
8
22
3.75
2.39
3.0
1.2
—
—
—
0
0
11
39
2.93
2.39
1.8
1.3
—
—
—
0
0
15
65
2.42
2.38
2.7
1.9
36.47
44.08
u/l
0.51
15
55
7
17
4.24
2.38
1.0
1.4
—
—
—
0
0
8
23
3.59
2.30
3.0
1.2
—
—
—
0
0
109
889
1.56
2.23
6.9
2.9
82.16
44.15
u/l
1.88
104
821
9
31
3.00
2.10
3.9
2.1
113.78
129.14
g/l
—
9
22
5
10
5.10
2.08
2.4
3.7
0.80
1.00
%
—
5
10
5
10
5.10
2.08
1.0
1.1
—
—
—
0
0
6
15
4.10
2.05
2.8
1.3
3.53
3.06
u/ml
—
6
15
7
21
3.42
1.98
2.3
11.3
10.01
6.69
mmol/l
—
7
15
27
161
1.79
1.91
5.6
3.1
—
—
—
0
0
11
46
2.48
1.89
2.5
1.2
—
—
—
0
0
101
831
1.48
1.85
7.7
4.3
0.00
9.18
estimate
0.50
27
177
9
36
2.58
1.76
1.4
1.2
—
—
—
0
0
6
18
3.41
1.76
1.0
1.2
—
—
—
0
0
20
113
1.86
1.68
4.3
2.4
41.80
64.16
ml/min/173m2
—
10
37
17
91
1.96
1.67
5.7
2.3
1.42
1.16
%
0.33
17
91
62
472
1.47
1.64
9.5
4.3
0.00
0.00
estimate
-0.00
25
154
70
550
1.44
1.56
4.9
3.9
16.52
6.86
mg/mmol
1.24
51
339
98
820
1.42
1.54
8.0
4.3
0.00
0.00
estimate
-0.00
26
169
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
15
3.40
1.53
1.2
1.1
—
—
—
0
0
5
16
3.18
1.44
1.2
1.1
—
—
—
0
0
5
16
3.18
1.44
5.2
4.1
864.80
795.13
mg
—
5
16
7
29
2.47
1.40
3.0
1.4
1532.71
360.73
mu/l
—
7
29
16
90
1.85
1.38
5.3
2.3
0.63
0.63
%
0.02
16
90
5
17
2.99
1.37
1.2
1.1
—
—
—
0
0
98
835
1.37
1.31
8.0
4.4
0.00
0.02
estimate
0.50
25
162
50
638
0.70
1.31
2.4
1.9
1.43
1.25
mmol/l
1.06
44
529
132
1425
0.74
1.03
5.5
5.3
1.40
1.48
mmol/l
1.18
123
1296
51
405
1.36
1.03
6.0
2.8
348.98
350.32
umol/l
0.02
44
349
9
48
1.92
1.02
1.6
1.2
—
—
—
0
0
13
76
1.76
1.02
41.4
4.5
1.78
1.55
%
0.26
13
71
123
1113
1.32
0.97
4.9
4.3
15.06
14.95
pmol/l
0.15
116
991
134
1433
0.76
0.86
5.7
5.4
4.14
4.52
mmol/l
4.44
126
1314
8
48
1.70
0.80
1.6
1.2
—
—
—
0
0
5
24
2.11
0.75
2.8
2.0
104.60
106.38
mmol/l
—
5
24
5
24
2.11
0.75
2.8
2.0
1.15
1.21
mmol/l
—
5
24
34
425
0.75
0.74
5.6
4.9
19.42
22.35
%
0.47
22
227
5
27
1.87
0.69
13.2
2.7
19.60
17.37
u/ml
—
5
27
9
138
0.63
0.63
2.1
1.4
—
—
—
0
0
31
249
1.29
0.59
1.2
1.3
7.11
8.50
u/ml
—
9
91
139
1460
0.80
0.58
6.1
6.4
2.26
2.61
mmol/l
4.91
130
1333
6
100
0.59
0.53
1.0
2.1
—
—
—
0
0
25
306
0.79
0.47
2.9
3.5
0.72
0.82
ug/l
0.26
18
211
10
69
1.48
0.45
1.5
1.4
—
—
—
0
0
129
1353
0.84
0.45
5.2
4.5
1.33
1.25
mmol/l
0.73
121
1219
136
1420
0.84
0.44
5.7
5.7
6.25
6.04
mmol/l
0.77
126
1283
150
1443
1.22
0.43
59.1
14.8
27.94
23.43
mg/l
1.10
143
1179
5
34
1.48
0.40
1.2
1.4
—
—
—
0
0
5
34
1.48
0.40
6.0
2.2
15.58
7.52
pmol/l
—
5
34
33
283
1.20
0.38
1.2
1.3
95.14
30.81
iu/ml
—
7
94
48
536
0.86
0.36
5.5
6.1
2.38
3.05
ug/l
0.36
43
468
6
43
1.41
0.35
1.3
1.6
—
—
—
0
0
6
89
0.66
0.33
1.0
1.9
—
—
—
0
0
68
632
1.12
0.28
9.0
4.2
0.00
0.00
estimate
-0.00
23
141
120
1154
1.12
0.26
59.1
20.4
15.02
13.79
%
8.56
120
1143
41
375
1.12
0.22
8.8
4.8
1.02
1.02
kg/l
0.11
34
261
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
33.38
—
0
8
0
14
0.00
0.20
0.0
1.1
—
607.00
—
0
8
151
1539
0.89
0.19
79.6
24.7
37.27
39.93
%
8.73
151
1520
151
1539
0.89
0.19
78.5
24.5
122.12
134.13
g/l
13.02
151
1520
151
1538
0.90
0.18
77.7
24.2
92.64
91.33
fl
1.91
151
1519
9
82
1.10
0.15
4.8
3.2
3.64
4.25
pmol/l
—
9
71
33
348
0.94
0.09
1.4
1.2
0.94
1.06
u/ml
—
10
90
6
72
0.83
0.08
1.0
1.0
—
—
—
0
0
19
204
0.92
0.07
15.4
7.9
—
—
—
0
0
21
224
0.93
0.07
4.4
5.0
34.56
32.30
%
0.31
16
133
137
1354
1.05
0.06
5.9
5.4
2.12
1.97
mu/l
0.61
128
1208
138
1393
0.96
0.05
8.2
7.1
40.62
39.71
mmol/mol
0.53
131
1285
46
447
1.04
0.04
7.3
3.5
0.00
0.00
estimate
-0.00
21
135
151
1522
0.95
0.04
65.2
21.4
107.37
79.41
umol/l
3.73
151
1502
21
200
1.06
0.04
1.5
1.4
—
—
—
0
0
18
189
0.95
0.03
1.7
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
88.71
—
0
7
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
51.56
—
0
9
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
13.29
—
0
7
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint AB1_LISTERIOSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_LISTERIOSIS | 4.859 [2.89, 8.17] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.824 |
During the follow-up period (1.1.1998 — 31.12.2019), 205 out of 348 females with AB1_LISTERIOSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_LISTERIOSIS | 4.353 [2.43, 7.78] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 223 out of 356 males with AB1_LISTERIOSIS died.
Mortality risk
Mortality risk for people of age
years, who have AB1_LISTERIOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.565% | 0.673% |
| 5 | 3.177% | 4.698% |
| 10 | 7.736% | 11.197% |
| 15 | 14.768% | 20.144% |
| 20 | 25.68% | 32.273% |
Relationships between endpoints
↥Index endpoint: AB1_LISTERIOSIS – Listeriosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data